AfterRaise/Companies/WhiteLab Genomics

WhiteLab Genomics

WhiteLab Genomics is a provider of an AI platform for designing genomic medicines. From its funding announcement.

$26M Series BRaised yesterdayParis, FranceBiotech & PharmaFrance

In their own words

What WhiteLab Genomics says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "provider of an AI platform for designing genomic medicines". Source

Market expansionProductCommercial growthUS expansionEuropean expansionAsia expansion

Public signal Read from the company's own description of what the funding supports.

Why now

Where WhiteLab Genomics is today

WhiteLab Genomics announced a Series B round of $26M on 6 October 2026, led by AVP.

Latest round
Series B
Amount
$26M
Announced
6 October 2026
Headquarters
Paris, France
Sector
Biotech & Pharma
Investors
Also participating
Yaday Health, Blast Club, Omnes, Debiopharm
Relevant leadership
CEO David Del Bourgo

Momentum AfterRaise intelligence

AfterRaise Score

74
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
16/25
round size relative to the market
Funding stage
18/20
Series B
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 6 October 2026
    $26M Series B
    Led by AVP.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Asia market entry
  • European market entry
  • US market entry
  • New market entry

Opportunities this could create

  • Scientific hiring
  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure
  • In-market partnerships

Based on the Biotech & Pharma sector, a Series B round and the priorities the company itself set out. Not a statement of fact.

High momentum7 connected signals
  • 6 October 2026$26M Series B announced
  • 6 October 2026Stated priority: market expansion
  • 6 October 2026Stated priority: product
  • 6 October 2026Stated priority: commercial growth
  • 6 October 2026Stated intent: us expansion AfterRaise intelligence
  • 6 October 2026Stated intent: european expansion AfterRaise intelligence

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What WhiteLab Genomics is open to

Not yet specified

WhiteLab Genomics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with WhiteLab Genomics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at WhiteLab Genomics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website and the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector